MGTA - Magenta Is Ready to Paint Your Portfolio Green
For patients with certain blood cancers, a stem cell transplant can often be a curative treatment. However, it is also a complex process riddled with severe toxicities and high rates of relapse or failure. These issues are at least part of the reason why only about 60% of cancer patients, a third of genetic disease patients, and 5% of autoimmune patients who are eligible to receive a stem cell transplant actually receive one. It's not hard to imagine that should a safer, more efficient process exist, the market could potentially expand. Enter Magenta Therapeutics (NASDAQ: MGTA) .
The clinical-stage biotech's lead compound, MGTA-145, has the potential to revolutionize the current standard-of-care transplant process for both patients and donors, making it faster and safer for all parties.
Image Source: Getty Images.
For further details see:
Magenta Is Ready to Paint Your Portfolio Green